排序方式: 共有30条查询结果,搜索用时 15 毫秒
21.
22.
23.
Stephanie B. Dixon Adam Lane Maureen M. O'Brien Karen C. Burns Jennifer L. Mangino Erin H. Breese Michael J. Absalon John P. Perentesis Christine L. Phillips 《Pediatric blood & cancer》2018,65(1)
1 Background
While viral surveillance of cytomegalovirus (CMV), Epstein–Barr virus (EBV), and adenovirus using PCR is routine in patients undergoing hematopoetic stem cell transplant and solid organ transplant, the utility in the nontransplant pediatric leukemia population is unknown. Our institution screens patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) for viral DNAemia by PCR as part of clinical care.2 Procedure
This retrospective chart review included patients treated for newly diagnosed or relapsed AML or ALL between April 2010 and September 2014. We retrieved data for viral PCR screening, detection and quantification, duration of positivity, and prophylaxis or treatment.3 Results
One hundred eleven patients were included in analyses. Forty (36.0%) had at least one blood PCR positive for EBV, CMV, or adenovirus. Patients with ALL had significantly higher rates of persistent viral detection and treatment than those with AML (P < 0.02, P < 0.01, respectively). International patients had significantly higher rates of viral detection (P < 0.01), persistence (P < 0.01), any treatment (P < 0.03), and antiviral treatment (P < 0.01); 16.9% of patients who received intravenous immunoglobulin (IVIG) prophylactically had viral detection compared to 63% of patients who did not receive prophylactic IVIG (P = 0.0008).4 Conclusions
Patients with ALL were more susceptible than those with AML to viral reactivation that was persistent or resulted in treatment. Patients with relapsed ALL, refractory ALL, or infantile ALL are most likely to benefit from asymptomatic screening for CMV and adenovirus. International patients are at higher risk for reactivation and may merit screening. EBV reactivation was not significant and does not warrant screening. 相似文献24.
Absalon J Fuller CM Ompad DC Blaney S Koblin B Galea S Vlahov D 《AIDS and behavior》2006,10(6):707-715
We compared sexual behaviors/partnerships and determined sexual risk correlates associated with HIV by gender among street-recruited drug users using chi-square tests and logistic regression. Men reported higher risk sexual behaviors, yet fewer high-risk sexual partners than women. After adjustment, HIV seropositive men were more likely than seronegatives to be older, MSM, use condoms, and have an HIV-infected partner. HIV seropositive women were more likely to be older, have an HIV-infected partner, and not use non-injected heroin. IDU was not associated with HIV. Prospective studies are needed to determine how gender-specific sexual behaviors/partnerships among drug users affect HIV acquisition. 相似文献
25.
Leigh syndrome is an encephalomyelopathy that results from a heterogeneous group of mitochondrial disorders characterized by symmetric brainstem spongioform lesions. An infant born with hypotonia and lactic acidosis was found to have symmetric brainstem lesions on T(2)-weighted magnetic resonance imaging consistent with Leigh syndrome. Muscle biopsy failed to reveal ragged-red fibers or cells devoid of cytochrome C oxidase or succinate dehyrogenase. Southern blot analysis of mitochondrial DNA isolated from the patient's quadriceps muscle indicated severe mitochondrial DNA depletion, which was suggested as the cause for the Leigh syndrome seen in this patient. Consideration of mitochondrial DNA depletion as an etiology when evaluating the patient with Leigh syndrome is encouraged. 相似文献
26.
Timo Vesikari Lars ?stergaard Johannes Beeslaar Judith Absalon Joseph J. Eiden Kathrin U. Jansen Thomas R. Jones Shannon L. Harris Roger Maansson Samantha Munson Robert E. ONeill Laura J. York John L. Perez 《Vaccine》2019,37(12):1710-1719
Background
The period of heightened risk of invasive meningococcal disease in adolescence extends for >10?years. This study aimed to evaluate persistence of the immune response to the serogroup B meningococcal (MenB) vaccine MenB-FHbp (Trumenba®, Bivalent rLP2086) under two- and three-dose primary vaccination schedules, both of which are approved in the United States and the European Union, and to assess safety and immunogenicity of a booster dose.Methods
This was an open-label extension study of a phase 2 randomized MenB-FHbp study (primary study). This interim analysis includes data through 1?month after booster vaccination. In the primary study, adolescents 11–18?years of age were randomized using an interactive voice or web-based response system to receive 120?μg MenB-FHbp under 0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month schedules (termed study groups for the current analysis). For the primary study, participants were blinded to their vaccine study group allocation, but investigators and the study sponsor were unblinded. Immune responses in subjects from the primary study were evaluated through 48?months after primary vaccination (persistence stage; 17 sites in Czech Republic, Denmark, Germany, and Sweden). Safety and immunogenicity of a booster dose given at 48?months after primary vaccination (booster stage; 14 sites in Czech Republic, Denmark, and Sweden) were also assessed. Immune responses were evaluated in serum bactericidal assays with human complement (hSBAs) using four MenB test strains representative of disease-causing MenB strains in the United States and Europe and expressing factor H binding proteins (FHbps) heterologous to the vaccine antigens. The primary immunogenicity endpoints were the proportions of subjects with hSBA titers greater than or equal to the assays’ lower limit of quantitation (LLOQ; 1:8 or 1:16 depending on strain) at 12, 18, 24, 36, and 48?months after primary vaccination (persistence stage) and 1 and 48?months after the primary vaccination series and 1?month after receipt of the booster dose (booster stage). Safety evaluations during the booster stage included local reactions and systemic events by severity, antipyretic use, adverse events (AEs), immediate AEs, serious AEs (SAEs), medically attended AEs (MAEs), newly diagnosed chronic medical conditions (NDCMCs), and missed days of school and work because of AEs. The modified intent-to-treat (mITT) population was used for immunogenicity evaluations in the persistence stage. The booster stage immunogenicity evaluations used the evaluable immunogenicity population; analyses were also performed in the mITT population. For the persistence stage, safety evaluations included subjects with at least one blood draw, whereas for the booster stage, they included subjects who received the booster dose and had available safety data. This trial is registered at ClinicalTrials.gov number NCT01543087.Findings
A total of 465 subjects were enrolled in the persistence stage, and 271 subjects were enrolled in the booster stage. Sera for the extension phase of this interim analysis were collected from September 7, 2012 to December 7, 2015. One month after primary vaccination, 73.8–100.0% of subjects depending on study group responded with hSBA titers ≥LLOQ. Response rates declined during the 12?months after last primary vaccination and then remained stable through 48?months, with 18.0–61.3% of subjects depending on study group having hSBA titers ≥LLOQ at this time point. One month after receipt of the booster dose, 91.9–100.0% of subjects depending on study group had hSBA titers ≥LLOQ against the four primary strains individually and 91.8–98.2% had hSBA titers ≥LLOQ against all four strains combined (composite response). Geometric mean titers were higher after booster vaccination than at 1?month after primary vaccination. Immune responses were generally similar across study groups, regardless of whether a two- or three-dose primary series was received. None of the AEs (2.2–6.9% of subjects depending on study group) or NDCMCs (1.8–5.0%) that were reported during the persistence stage were considered related to the investigational product. Local reactions and systemic events were reported by 84.4–93.8% and 68.8–76.6% of subjects depending on study group, respectively, in the booster stage; these were generally similar across study groups, transient, and less frequent than after any primary vaccination. Additionally, there was no general progressive worsening in severity of reactogenicity events (ie, potentiation; ≤3 subjects per group), and reactogenicity events did not lead to any study withdrawals. No NDCMCs or immediate AEs were reported during the booster stage. AEs were reported by 3.7–12.5% of subjects depending on study group during the booster stage. The two possibly related AEs included a mild worsening of psoriasis and a severe influenza-like illness that resolved in 10?days.Interpretation
Immune responses declined after the primary vaccination series; however, a substantially greater number of subjects retained protective responses at 48?months after primary vaccination compared with subjects having protective responses before vaccination. Persistence trends were similar across all 5 study groups regardless of whether a two- or three-dose primary schedule was received. Furthermore, a booster dose given 48?months after primary vaccination was safe, well-tolerated, and elicited robust immune responses indicative of immunologic memory; these responses were similar between two- and three-dose primary schedule study groups. Use of a booster dose may help further extend protection against MenB disease in adolescents.Funding
Pfizer Inc. 相似文献27.
Background
Altered FDG uptake patterns were noted in certain lymphoblastic lymphoma patients during therapy. 相似文献28.
Laetitia Houot Sarah Chang Cedric Absalon Paula I. Watnick 《Infection and immunity》2010,78(4):1482-1494
The bacterial phosphoenolpyruvate phosphotransferase system (PTS) is a highly conserved phosphotransfer cascade whose components modulate many cellular functions in response to carbohydrate availability. Here, we further elucidate PTS control of Vibrio cholerae carbohydrate transport and activation of biofilm formation on abiotic surfaces. We then define the role of the PTS in V. cholerae colonization of the adult germfree mouse intestine. We report that V. cholerae colonizes both the small and large intestines of the mouse in a distribution that does not change over the course of a month-long experiment. Because V. cholerae possesses many PTS-independent carbohydrate transporters, the PTS is not essential for bacterial growth in vitro. However, we find that the PTS is essential for colonization of the germfree adult mouse intestine and that this requirement is independent of PTS regulation of biofilm formation. Therefore, competition for PTS substrates may be a dominant force in the success of V. cholerae as an intestinal pathogen. Because the PTS plays a role in colonization of environmental surfaces and the mammalian intestine, we propose that it may be essential to successful transit of V. cholerae through its life cycle of pathogenesis and environmental persistence.In water, in soil, and in the eukaryotic host, bacteria survive by monitoring their environment and continuously adjusting their nutrient uptake and catabolism machinery to mirror environmental availability. While the ability to maximize environmental nutrients may not be critical in nutrient-rich environments such as those found in the laboratory, in natural environments where nutrients are scarce and competition for these nutrients may be fierce, rapid and precise adaptation is the key to survival.The bacterial phosphoenolpyruvate phosphotransferase system (PTS) is a multicomponent phosphotransfer cascade that coordinates transport and phosphorylation of selected carbohydrates through PTS-associated transporters. Because transport of PTS substrates rapidly depletes the PTS of phosphorylated intermediates, the phosphorylation states of PTS components serve as cytoplasmic reporters of environmental nutrient availability (5).Phosphotransfer through the PTS is initiated when the cytoplasmic phosphoenolpyruvate-protein phosphotransferase, or enzyme I (EI), accepts a phosphate from phosphoenolpyruvate. EI is required for the transport of all PTS substrates. EI transfers its phosphate group to histidine protein (HPr), another cytoplasmic protein involved in the transport of most PTS substrates. HPr transfers its phosphate to any of a number of enzymes II, which are membrane-associated complexes that carry out the transport and phosphorylation of specific PTS substrates and comprise multiple subunits (EIIA, EIIB, EIIC, and sometimes EIID). A fructose-specific multidomain protein, FPr, which consists of an N-terminal EIIA-like domain, a central domain of unknown function, and a C-terminal HPr-like domain, is also present in many Gram-negative bacteria (15). In the transport of fructose by the Escherichia coli PTS, FPr is favored over HPr in the phosphotransfer cascade. Furthermore, a parallel PTS system is encoded by many bacterial genomes (29, 30). This system is termed the PTSNtr because of its chromosomal proximity to the genes encoding the nitrogen-specific sigma factor, σ54. The PTSNtr includes an EI homolog (EINtr), an HPr homolog (NPr), and an EIIA homolog (EIIANtr). Although there is some evidence of cross talk between the carbon-specific PTS and the PTSNtr (26), the latter system is thought to function primarily in regulation rather than transport.Vibrio cholerae is a Gram-negative, halophilic bacterium that inhabits saline and freshwater aquatic environments (6). In these environments, V. cholerae is hypothesized to attach to abiotic surfaces by elaboration of an exopolysaccharide termed VPS in a process known as VPS-dependent biofilm formation (40). Many of the vps genes, which are required for VPS synthesis, are carried in two large operons consisting of vpsA to vpsK and vpsL to vpsQ (39).Some strains of V. cholerae are also able to cause the human diarrheal disease cholera after ingestion in contaminated food or water. Disease requires the presence of the toxin-coregulated pilus, the primary intestinal colonization factor of V. cholerae (9, 35), as well as cholera toxin, which acts on the epithelial cells of the small intestine to produce an intense, osmotic diarrhea. Therefore, the ability to colonize the small intestine is an important component in V. cholerae virulence.We hypothesized that to persist in all these environments, V. cholerae must sense and respond to preferred carbon sources and, therefore, that the regulatory and transport functions of the PTS might figure prominently in its success. Only two studies thus far have examined the transport and regulatory functions of V. cholerae PTS components. One of these documented a regulatory function for the phosphorylated form of EI in the repression of VPS-dependent biofilm formation on abiotic surfaces (12), while the other identified the chitobiose transport apparatus (1). In this work, we performed a mutagenesis-based study of the roles of V. cholerae PTS components in sugar transport and VPS-dependent biofilm formation. To evaluate the role of the PTS signal transduction cascade in the colonization of the adult mammalian intestine, we implemented and characterized an adult germfree mouse model of disease. We have shown that V. cholerae is present in the distal small intestine as well as the large intestine and have found that the requirement for the PTS in intestinal colonization is independent of VPS synthesis. These results suggest a role for the V. cholerae PTS in the colonization of environmental surfaces and the adult mammalian intestine. The PTS is found in almost all bacterial species and has been shown previously to play important roles in the surface attachment and virulence of many of these species (14, 16, 18, 27, 31, 33, 34). Because the PTS is also highly conserved, we suggest that it may be an excellent target for inhibition of colonization of both environmental surfaces and host epithelia by diverse bacteria. 相似文献
29.
30.
D Hatton M Muntzel J Absalon D Lashley D A McCarron 《The American journal of clinical nutrition》1991,53(2):542-546
Supplemental dietary calcium in spontaneously hypertensive rats (SHRs) aged 21-28 d produces a decrease in blood pressure and hematocrit. The simultaneous fall in hematocrit and blood pressure suggests that the changes in blood pressure may be, in part, a consequence of the decrease in hematocrit and reduction in viscosity. To examine this possibility, SHRs aged 21 d were placed on one of four diets varying in iron content. At age 28, the animals showed iron-induced variations in hematocrit (P less than 0.001) but no difference in blood pressure. Subsequent manipulation of the ratio of calcium and iron in the diets of additional groups of animals resulted in variations in hematocrit that were independent of the calcium-induced alterations in blood pressure. We conclude that the effects of calcium on blood pressure are relatively independent of its effects on hematocrit. 相似文献